1Schimke J,Mathison J,Morgiewicz J,et al. Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin [in process citation]. Proc Natl Acad Sci USA, 1998, 95: 13875～13880.
2Suter PM,Suter S,Girardin E,et al. Alveolar 74. Spits H et al. Arch Allergy Immunol, 1992,99: 9 ～ 15.
3Martin TR,Ruzinski JT,Steinberg KP,et al. Cytokine balance in the lungs of patients with acute respiratory distress syndrome (ARDS).Am J Respir Crit Care Med, 1998,157: A679.
4Goodman RB,Strieter Rm,Steinberg KP,et al. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med,1996,154:602～611.
5Van der Poll T,Marchant A,Keogh CV,et al. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis, 1996,174:994～1000.
6Taga M,Howard M,Giovanna T. Human interlerkin-10 can directly inhibit T-cell growth. Blood, 1993,81 (11): 2964～ 2971.
7Donnelly SC. Strieter RM,Reid PT,et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distess syndrome. Ann Intern Med, 1996,125:191～196.
8Martin TR,Donnelly SC,Steinberg KP,et al. Macrophage inhibitory factor(MIF)in the lungs of patients with acute respiratory distress syndrome (ARDS) [abstract]. Am J Respir Crit Care med, 1998,157:A459.
9Schwartz MD,Moore EE,Moore FA,et al. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med,1996,24(8):1285～1292.
10Blackewell TR,Holden EP. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol, 1996, (7), 157:1630～ 1637.
